X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs GLENMARK PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD GLENMARK PHARMA MERCK LTD/
GLENMARK PHARMA
 
P/E (TTM) x 26.1 13.9 188.5% View Chart
P/BV x 2.9 3.9 75.3% View Chart
Dividend Yield % 1.0 0.3 295.7%  

Financials

 MERCK LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
GLENMARK PHARMA
Mar-16
MERCK LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0601,262 84.0%   
Low Rs623672 92.8%   
Sales per share (Unadj.) Rs632.4270.6 233.8%  
Earnings per share (Unadj.) Rs45.724.9 183.8%  
Cash flow per share (Unadj.) Rs62.334.4 181.1%  
Dividends per share (Unadj.) Rs11.002.00 550.0%  
Dividend yield (eoy) %1.30.2 631.9%  
Book value per share (Unadj.) Rs388.8151.3 256.9%  
Shares outstanding (eoy) m16.60282.16 5.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.6 37.2%   
Avg P/E ratio x18.438.9 47.4%  
P/CF ratio (eoy) x13.528.1 48.1%  
Price / Book Value ratio x2.26.4 33.9%  
Dividend payout %24.18.0 299.3%   
Avg Mkt Cap Rs m13,969272,778 5.1%   
No. of employees `0001.610.0 15.8%   
Total wages/salary Rs m1,48713,782 10.8%   
Avg. sales/employee Rs Th6,631.97,614.9 87.1%   
Avg. wages/employee Rs Th939.21,374.8 68.3%   
Avg. net profit/employee Rs Th479.4700.2 68.5%   
INCOME DATA
Net Sales Rs m10,49876,340 13.8%  
Other income Rs m242356 68.0%   
Total revenues Rs m10,74176,696 14.0%   
Gross profit Rs m1,13514,172 8.0%  
Depreciation Rs m2762,691 10.2%   
Interest Rs m01,789 0.0%   
Profit before tax Rs m1,10210,048 11.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3433,028 11.3%   
Profit after tax Rs m7597,019 10.8%  
Gross profit margin %10.818.6 58.3%  
Effective tax rate %31.130.1 103.3%   
Net profit margin %7.29.2 78.6%  
BALANCE SHEET DATA
Current assets Rs m6,41059,096 10.8%   
Current liabilities Rs m8,82840,018 22.1%   
Net working cap to sales %-23.025.0 -92.2%  
Current ratio x0.71.5 49.2%  
Inventory Days Days5875 76.9%  
Debtors Days Days38119 32.2%  
Net fixed assets Rs m1,40639,075 3.6%   
Share capital Rs m166282 58.8%   
"Free" reserves Rs m6,28630,281 20.8%   
Net worth Rs m6,45542,703 15.1%   
Long term debt Rs m024,873 0.0%   
Total assets Rs m8,828111,026 8.0%  
Interest coverage xNM6.6-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.7 172.9%   
Return on assets %8.67.9 108.4%  
Return on equity %11.816.4 71.5%  
Return on capital %17.117.5 97.5%  
Exports to sales %8.343.3 19.1%   
Imports to sales %21.07.4 283.2%   
Exports (fob) Rs m86933,044 2.6%   
Imports (cif) Rs m2,2095,672 38.9%   
Fx inflow Rs m95936,945 2.6%   
Fx outflow Rs m2,61261,066 4.3%   
Net fx Rs m-1,653-24,122 6.9%   
CASH FLOW
From Operations Rs m1,0703,449 31.0%  
From Investments Rs m-750-8,802 8.5%  
From Financial Activity Rs m-1506,986 -2.1%  
Net Cashflow Rs m171934 18.3%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 6.9 263.8%  
FIIs % 1.0 34.4 2.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 10.5 277.1%  
Shareholders   28,591 56,727 50.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  ELDER PHARMA  VENUS REMEDIES  

Compare MERCK LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - ELDER PHARMA COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS